mutation class

Chromosomal Aberration

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

147 sites for NCT04293562

BCR-ABL1 Fusion, +48 more biomarkers

Acute Myeloid Leukemia

allogeneic hematopoietic stem cell transplantation, +12 more drugs

cellular therapy, +4 more types

A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

198 sites for NCT04102020

BCR-ABL1 Fusion, +47 more biomarkers

Acute Myeloid Leukemia

azacitidine, +1 more drug

chemotherapy

Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)

14 sites for NCT04571645

ASXL1 Loss, +27 more biomarkers

Acute Myeloid Leukemia

chemotherapy, +1 more drug

chemotherapy, +1 more type

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

1 site for NCT04797767

ASXL1 Loss, +23 more biomarkers

Acute Biphenotypic Leukemia, +2 more conditions

cladribine, +4 more drugs

chemotherapy, +1 more type

Venetoclax, Busulfan, Cladribine, and Fludarabine for the Treatment of High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

1 site for NCT04708054

ARAF Mutation, +47 more biomarkers

Acute Myeloid Leukemia, +2 more conditions

busulfan, +5 more drugs

cellular therapy, +1 more type

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies

1 site for NCT04990323

ASXL1 Loss, +23 more biomarkers

Acute Myeloid Leukemia, +4 more conditions

ECT-001 expanded cord blood

cellular therapy